Wang Xiao-ping, Zhang Jun-hua, Wang Yu-jiong, Feng Ying, Zhang Xi, Sun Xiao-xia, Li Ji-liang, Du Xue-ting, Lambert Mary P, Yang Shi-gao, Zhao Min, Klein William L, Liu Rui-tian
Tsinghua University, School of Medicine, Haidian District, Beijing 100084, China.
FEBS Lett. 2009 Feb 4;583(3):579-84. doi: 10.1016/j.febslet.2008.12.064. Epub 2009 Jan 20.
Increasing evidence indicates that beta-amyloid (Abeta) oligomers rather than monomers or fibrils are the major toxic agents that specifically inhibit synaptic plasticity and long-term potentiation (LTP) in Alzheimer's disease (AD). Neutralization of Abeta oligomeric toxicity was found to reverse memory deficits. Here, we report four single-chain variable fragment (scFv) antibodies isolated from the naive human scFv library by phage display that specifically recognized Abeta oligomers but not monomers and fibrils. These conformation-dependent scFv antibodies inhibit both Abeta fibrillation and cytotoxicity and bind to the same type of eptitope displayed on the Abeta oligomers. Such scFv antibodies specifically targeting toxic Abeta oligomers may have potential therapeutic and diagnostic applications for AD.
越来越多的证据表明,在阿尔茨海默病(AD)中,β-淀粉样蛋白(Aβ)寡聚体而非单体或纤维是特异性抑制突触可塑性和长时程增强(LTP)的主要毒性因子。发现中和Aβ寡聚体毒性可逆转记忆缺陷。在此,我们报告了通过噬菌体展示从天然人单链可变片段(scFv)文库中分离出的四种单链可变片段抗体,它们特异性识别Aβ寡聚体而非单体和纤维。这些构象依赖性scFv抗体既能抑制Aβ纤维化又能抑制细胞毒性,并与Aβ寡聚体上展示的同一类型表位结合。这种特异性靶向有毒Aβ寡聚体的scFv抗体可能对AD具有潜在的治疗和诊断应用。